We examined whether pramipexole (PPX) can influence depressive scale in normal and mild depressive parkinsonian patients. In an open study of PPX as an add-on to L-dopa therapy or single administration, 36 nondemented outpatients with Parkinson's disease (PD) were entered first. All were in the stage II or III of Hoehn and Yahr scale (H&Y). PPX were started at 0.125 mg/day and daily doses were increased to 1.5 mg/day. At 3 months after PPX treatment, patients were re-evaluated. Hamilton Depression Rating Scale (HAM-D), Unified Parkinson's Disease Rating Scale III, H&Y stage, and freezing of gait questionnaire were compared in patients before and after PPX treatment. These scores were significantly improved after PPX administration. There were no correlations between HAM-D and those motor functions. We suggest that PPX treatment has antidepressant effects in depressive PD patients and also ameliorates HAM-D score in nondepressive PD patients in addition to motor function. © 2008 Kano et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Kano, O., Ikeda, K., Kiyozuka, T., Iwamoto, K., Ito, H., Kawase, Y., … Iwasaki, Y. (2008). Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease. Neuropsychiatric Disease and Treatment, 4(4), 707–710. https://doi.org/10.2147/ndt.s2921
Mendeley helps you to discover research relevant for your work.